Art. -Nr.: HY-100126

Tubercidin

(Synonyms: 7-Deazaadenosine)

8 Cited Publications

Kundenbewertung

Based on 8 publication(s) in Google Scholar

Tubercidin (7-Deazaadenosine) is an antibiotic obtained from Streptomyces tubercidicus. Tubercidin inhibits the growth of Streptococcus faecalis (8043) with an IC₅₀ of 0.02 μM. Tubercidin inhibits polymerases by incorporating DNA or RNA, thereby inhibiting DNA replication, RNA and protein synthesis. Tubercidin is a weak inhibitor of adenosine phosphorylase, and interferes with the phosphorylation of adenosine and AMP. Tubercidin has antiviral activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.24%
CAS. Nr.: 69-33-0
Formel: C₁₁H₁₄N₄O₄
Molecular Weight:266.26

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Tubercidin Chemical Structure

CAS. Nr.: 69-33-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (8)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Tubercidin (7-Deazaadenosine) is an antibiotic obtained from Streptomyces tubercidicus. Tubercidin inhibits the growth of Streptococcus faecalis (8043) with an IC₅₀ of 0.02 μM^[1]. Tubercidin inhibits polymerases by incorporating DNA or RNA, thereby inhibiting DNA replication, RNA and protein synthesis^[2]. Tubercidin is a weak inhibitor of adenosine phosphorylase, and interferes with the phosphorylation of adenosine and AMP^[1]. Tubercidin has antiviral activity^[2].

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen :

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	0.043 μM Compound: Tubercidin	Cytotoxicity against human A-375 cells assessed as cell growth inhibition Cytotoxicity against human A-375 cells assessed as cell growth inhibition	[PMID: 33132173]
A549	GI₅₀	0.001 μM Compound: Tubercidin	Cytostatic activity against human A549 cells after 5 days by SRB assay Cytostatic activity against human A549 cells after 5 days by SRB assay	[PMID: 21711054]
A549	IC₅₀	0.044 μM Compound: Tubercidin	Cytotoxicity against human A549 cells assessed as cell growth inhibition Cytotoxicity against human A549 cells assessed as cell growth inhibition	[PMID: 33132173]
CCRF-CEM	IC₅₀	0.11 μM Compound: 1; 1a; Tub	Cytotoxicity against human CCRF-CEM cells assessed as cell growth inhibition Cytotoxicity against human CCRF-CEM cells assessed as cell growth inhibition	[PMID: 35763869]
DU-145	GI₅₀	0.018 μM Compound: Tubercidin	Cytostatic activity against human DU145 cells after 5 days by SRB assay Cytostatic activity against human DU145 cells after 5 days by SRB assay	[PMID: 21711054]
DU-145	IC₅₀	0.256 μM Compound: Tubercidin	Cytotoxicity against human DU-145 cells assessed as cell growth inhibition Cytotoxicity against human DU-145 cells assessed as cell growth inhibition	[PMID: 33132173]
HCT-116	GI₅₀	0.001 μM Compound: Tubercidin	Cytostatic activity against human HCT116 cells after 5 days by SRB assay Cytostatic activity against human HCT116 cells after 5 days by SRB assay	[PMID: 21711054]
HCT-116	IC₅₀	0.082 μM Compound: Tubercidin	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition	[PMID: 33132173]
HCT-15	GI₅₀	0.011 μM Compound: Tubercidin	Cytostatic activity against human HCT15 cells after 5 days by SRB assay Cytostatic activity against human HCT15 cells after 5 days by SRB assay	[PMID: 21711054]
HEK293	IC₅₀	0.88 μM Compound: 4	Stabilization of Pdcd4 expressed in human HEK293 cells assessed as inhibition of TPA-induced degradation by luciferase reporter assay Stabilization of Pdcd4 expressed in human HEK293 cells assessed as inhibition of TPA-induced degradation by luciferase reporter assay	[PMID: 21870828]
HeLa S3	IC₅₀	0.03 μM Compound: 3	Antiviral activity against Poliovirus infected in human HeLaS3 cells assessed as inhibition of viral replication treated 1 hr before infection measured after 2 days Antiviral activity against Poliovirus infected in human HeLaS3 cells assessed as inhibition of viral replication treated 1 hr before infection measured after 2 days	[PMID: 20964406]
HeLa S3	IC₅₀	0.4 μM Compound: 3	Cytotoxicity against human HeLaS3 cells after 48 hrs by celltiter-glo assay Cytotoxicity against human HeLaS3 cells after 48 hrs by celltiter-glo assay	[PMID: 20964406]
HeLa S3	IC₅₀	0.819 μM Compound: 3	Cytotoxicity against human HeLaS3 cells after 24 hrs by celltiter-glo assay Cytotoxicity against human HeLaS3 cells after 24 hrs by celltiter-glo assay	[PMID: 20964406]
HeLa S3	IC₅₀	1.44 μM Compound: 3	Cytotoxicity against human HeLaS3 cells after 7 hrs by celltiter-glo assay Cytotoxicity against human HeLaS3 cells after 7 hrs by celltiter-glo assay	[PMID: 20964406]
HeLa S3	IC₅₀	0.1 μM Compound: 1; 1a; Tub	Cytotoxicity against human HeLa S3 cells assessed as cell growth inhibition Cytotoxicity against human HeLa S3 cells assessed as cell growth inhibition	[PMID: 35763869]
HEp-2	IC₅₀	>3 μM Compound: 4	Compound was evaluated for cytotoxicity against H.Ep.-2 (AK-) cells and concentration required to inhibit the growth of treated cells to 50% of untreated control Compound was evaluated for cytotoxicity against H.Ep.-2 (AK-) cells and concentration required to inhibit the growth of treated cells to 50% of untreated control	[PMID: 6708054]
HEp-2	IC₅₀	0.002 μM Compound: 4	Compound was evaluated for cytotoxicity against H.Ep.-2 cells, and concentration required to inhibit the growth of treated cells to 50% of untreated control. Compound was evaluated for cytotoxicity against H.Ep.-2 cells, and concentration required to inhibit the growth of treated cells to 50% of untreated control.	[PMID: 6708054]
HepG2	IC₅₀	0.05 μM Compound: 1; 1a; Tub	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition Cytotoxicity against human HepG2 cells assessed as cell growth inhibition	[PMID: 35763869]
HFF	IC₅₀	0.4 μM Compound: 1 tubercidin	Cytotoxicity against uninfected human foreskin fibroblast(HFF cells) Cytotoxicity against uninfected human foreskin fibroblast(HFF cells)	[PMID: 2846837]
HFF	IC₅₀	0.3 μM Compound: 8a	Cytotoxicity was evaluated against the Human diploid cells (HFF) Cytotoxicity was evaluated against the Human diploid cells (HFF)	[PMID: 2913300]
HFF	IC₅₀	0.79 μM Compound: Tubercidin	Cytotoxicity against human HFF cells assessed as cell growth inhibition Cytotoxicity against human HFF cells assessed as cell growth inhibition	[PMID: 33132173]
HFF	IC₅₀	0.4 μM Compound: 1a	Tested for cytotoxicity in human foreskin fibroblasts at time of HCMV plaque enumeration Tested for cytotoxicity in human foreskin fibroblasts at time of HCMV plaque enumeration	[PMID: 8254613]
HL-60	IC₅₀	0.14 μM Compound: 1; 1a; Tub	Cytotoxicity against human HL-60 cells assessed as cell growth inhibition Cytotoxicity against human HL-60 cells assessed as cell growth inhibition	[PMID: 35763869]
KB	IC₅₀	1 μM Compound: 1	Cytotoxicity of compound was determined by assaying cell growth in human neoplastic cell line(KB). Cytotoxicity of compound was determined by assaying cell growth in human neoplastic cell line(KB).	[PMID: 1310744]
KB	IC₅₀	0.6 μM Compound: 1 tubercidin	Cytotoxicity against human neoplastic cell line(KB cells) Cytotoxicity against human neoplastic cell line(KB cells)	[PMID: 2846837]
KB	IC₅₀	0.7 μM Compound: 8a	Cytotoxicity was evaluated in Human neoplastic cell line (KB) Cytotoxicity was evaluated in Human neoplastic cell line (KB)	[PMID: 2913300]
KB	IC₅₀	1 μM Compound: 1a	Tested for the inhibition against KB cell growth Tested for the inhibition against KB cell growth	[PMID: 8254613]
L1210	IC₅₀	0.04 μM Compound: 1	Concentration required to decrease the growth rate to 50% of control was evaluated by determining their ability to inhibit growth of L1210 cells in vitro. Concentration required to decrease the growth rate to 50% of control was evaluated by determining their ability to inhibit growth of L1210 cells in vitro.	[PMID: 1310744]
L1210	IC₅₀	4 x 10^-8 M Compound: 8a	In vitro cytotoxicity was evaluated against the L1210 Murine leukemic cells In vitro cytotoxicity was evaluated against the L1210 Murine leukemic cells	[PMID: 2913300]
L1210	IC₅₀	0.018 μg/mL Compound: 11	In vitro inhibition of L1210 (murine leukemia) cell growth. In vitro inhibition of L1210 (murine leukemia) cell growth.	[PMID: 6538600]
L1210	IC₅₀	6.77 x 10^-8 M Compound: 11	In vitro inhibition of L1210 (murine leukemia) cell growth. In vitro inhibition of L1210 (murine leukemia) cell growth.	[PMID: 6538600]
L1210	IC₅₀	0.043 μM Compound: 1a	Tested for in vitro cell growth inhibition of L1210 cells Tested for in vitro cell growth inhibition of L1210 cells	[PMID: 8254613]
L1210	IC₅₀	0.043 μM Compound: 5 (tubercidin)	Cytotoxicity in L1210 cell culture. Cytotoxicity in L1210 cell culture.	[PMID: 9057866]
Macrophage	CC₅₀	0.13 μM Compound: Tubercidin	Cytotoxicity against Swiss mouse peritoneal macrophages assessed as reduction in cell viability measured after 5 days by microscopic analysis Cytotoxicity against Swiss mouse peritoneal macrophages assessed as reduction in cell viability measured after 5 days by microscopic analysis	[PMID: 35144125]
MRC5	EC₅₀	2.23 μM Compound: 1	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 3 days by resazurin dye-based assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 3 days by resazurin dye-based assay	[PMID: 30677668]
MRC5	CC₅₀	2.23 μM Compound: Tubercidin	Cytotoxicity against human MRC5 fibroblast cells assessed as reduction in cell viability measured after 3 days by fluorometry Cytotoxicity against human MRC5 fibroblast cells assessed as reduction in cell viability measured after 3 days by fluorometry	[PMID: 35144125]
MT4	GI₅₀	0.021 μM Compound: Tubercidin	Cytostatic activity against human MT4 cells after 5 days by SRB assay Cytostatic activity against human MT4 cells after 5 days by SRB assay	[PMID: 21711054]
NCI-H23	GI₅₀	0.011 μM Compound: Tubercidin	Cytostatic activity against human NCI-H23 cells after 5 days by SRB assay Cytostatic activity against human NCI-H23 cells after 5 days by SRB assay	[PMID: 21711054]
NHDF	IC₅₀	0.07 μM Compound: 1; 1a; Tub	Cytotoxicity against human NHDF cells assessed as cell growth inhibition Cytotoxicity against human NHDF cells assessed as cell growth inhibition	[PMID: 35763869]
PC-3	GI₅₀	0.048 μM Compound: Tubercidin	Cytostatic activity against human PC3 cells after 5 days by SRB assay Cytostatic activity against human PC3 cells after 5 days by SRB assay	[PMID: 21711054]
PC-3	IC₅₀	0.076 μM Compound: Tubercidin	Cytotoxicity against human PC-3 cells assessed as cell growth inhibition Cytotoxicity against human PC-3 cells assessed as cell growth inhibition	[PMID: 33132173]
SK-OV-3	IC₅₀	0.131 μM Compound: Tubercidin	Cytotoxicity against human SK-OV-3 cells assessed as cell growth inhibition Cytotoxicity against human SK-OV-3 cells assessed as cell growth inhibition	[PMID: 33132173]
T47D	IC₅₀	0.013 μM Compound: Tubercidin	Cytotoxicity against human T47D cells assessed as cell growth inhibition Cytotoxicity against human T47D cells assessed as cell growth inhibition	[PMID: 33132173]
Vero	CC₅₀	>357 μM Compound: 4; 7-DMA	Cytotoxicity against African green monkey Vero cells by visual method Cytotoxicity against African green monkey Vero cells by visual method	[PMID: 31549836]
Vero	EC₅₀	1.3 μM Compound: 4; 7-DMA	Inhibition of RNA-dependent RNA polymerase in Zika virus MR766 infected in African green monkey Vero cells assessed as antiviral activity by Alexa Fluor 488/DAPI staining based assay Inhibition of RNA-dependent RNA polymerase in Zika virus MR766 infected in African green monkey Vero cells assessed as antiviral activity by Alexa Fluor 488/DAPI staining based assay	[PMID: 31549836]
Vero	EC₅₀	1.3 μM Compound: 4; 7-DMA	Inhibition of RNA-dependent RNA polymerase in Zika virus MR766 infected in African green monkey Vero cells assessed as antiviral activity by measuring reduction in virus-induced cytopathic effect after 5 days by MTS assay Inhibition of RNA-dependent RNA polymerase in Zika virus MR766 infected in African green monkey Vero cells assessed as antiviral activity by measuring reduction in virus-induced cytopathic effect after 5 days by MTS assay	[PMID: 31549836]
Vero	EC₅₀	1.3 μM Compound: 4; 7-DMA	Inhibition of RNA-dependent RNA polymerase in Zika virus MR766 infected in African green monkey Vero cells assessed as antiviral activity by measuring reduction in virus-yield Inhibition of RNA-dependent RNA polymerase in Zika virus MR766 infected in African green monkey Vero cells assessed as antiviral activity by measuring reduction in virus-yield	[PMID: 31549836]
Vero	EC₅₀	1.3 μM Compound: 4; 7-DMA	Inhibition of RNA-dependent RNA polymerase in Zika virus MR766 infected in African green monkey Vero cells assessed as antiviral activity by methylene blue staining based by Plaque reduction assay Inhibition of RNA-dependent RNA polymerase in Zika virus MR766 infected in African green monkey Vero cells assessed as antiviral activity by methylene blue staining based by Plaque reduction assay	[PMID: 31549836]
Vero C1008	EC₅₀	0.59 μM Compound: Tubercidin	Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as reduction in infection measured after 24 hrs by Plaque assay Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as reduction in infection measured after 24 hrs by Plaque assay	[PMID: 37229831]

In Vitro

Tubercidin (7-Deazaadenosine) (0-10 nM; 14 days) has a dose-dependent inhibitory effect on myeloid and erythroid human bone marrow progenitor cells, and the IC₅₀s of tubercidin are 3.4 nM and 3.7 nM for CFU-GM and BFU-E, respectively^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[2]

Cell Line:

Human bone marrow progenitor cells
Concentration:

0-10 nM
Incubation Time:

14 days
Result:

Had a dose-dependent inhibitory effect for CFU-GM and BFU-E.

In Vivo

Tubercidin (7-Deazaadenosine) (intraperitoneal injection; 5 mg/kg; 10 days) in cooperation with NBMPR-P protects the mice from the lethality of tubercidin and allowed the repetition of the regimen for a second time with 100% survival^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female CD1 mice^[2]
Dosage:

5 mg/kg
Administration:

Intraperitoneal injection; 5 mg/kg; 10 days
Result:

Protected the mice from the lethality of tubercidin.

Chemical Information

CAS. Nr. 69-33-0
Appearance Solid
Molecular Weight 266.26
Formel C₁₁H₁₄N₄O₄
Color White to off-white
SMILES

O[C@H]1[C@@H](O)[C@H](N2C=CC3=C2N=CN=C3N)O[C@@H]1CO
Synonyms

7-Deazaadenosine
Structure Classification
- Antibiotics
- Other Antibiotics
Initial Source
- Microorganisms
Streptomyces tubercidicus
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (8)

All

Sort by:

Journal Impact Factor

Elife

Overcoming the cytoplasmic retention of GDOWN1 modulates global transcription and facilitates stress adaptation. [Abstract]

2022 Dec 7:11:e79116. PMID: 36476745
Microb Cell Fact

Discovery and characterization of the tubercidin biosynthetic pathway from Streptomyces tubercidicus NBRC 13090. [Abstract]

2018 Aug 28;17(1):131. PMID: 30153835
J Med Virol

Drug Repurposing: In Vitro Evaluation of Simeprevir as a Novel Antiviral Drug Against Severe Fever With Thrombocytopenia Syndrome Virus. [Abstract]

2025 Oct;97(10):e70655. PMID: 41117261
Microbiol Spectr

Tubercidin inhibits PRRSV replication via RIG-I/NF-κB pathways and interrupting viral nsp2 synthesis. [Abstract]

2024 Mar 5;12(3):e0347923. PMID: 38299833
J Chromatogr B Analyt Technol Biomed Life Sci

Exploring urinary modified nucleosides as biomarkers for diabetic retinopathy: Development and validation of a ultra performance liquid chromatography-tandem mass spectrometry method. [Abstract]

2024 Jan 1:1232:123968. PMID: 38150972
Res Sq

2026 Mar 5.
bioRxiv

2025 July 11.
bioRxiv

2024 July 27.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 30 mg/mL (112.67 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.7557 mL

18.7786 mL

37.5573 mL

5 mM

0.7511 mL

3.7557 mL

7.5115 mL

10 mM

0.3756 mL

1.8779 mL

3.7557 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Bloch A, et al. On the mode of action of 7-deaza-adenosine (Tubercidin). Biochim Biophys Acta. 1967 Mar 29;138(1):10-25. [Content Brief]

[2]. Bergstrom DE, et al. Antiviral activity of C-5 substituted tubercidin analogues. J Med Chem. 1984 Mar;27(3):285-92. [Content Brief]

[3]. Kouni MH, et al. Prevention of tubercidin host toxicity by nitrobenzylthioinosine 5'-monophosphate for the treatment of schistosomiasis. Antimicrob Agents Chemother. 1989 Jun;33(6):824-7. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.7557 mL	18.7786 mL	37.5573 mL	93.8932 mL
	5 mM	0.7511 mL	3.7557 mL	7.5115 mL	18.7786 mL
	10 mM	0.3756 mL	1.8779 mL	3.7557 mL	9.3893 mL
	15 mM	0.2504 mL	1.2519 mL	2.5038 mL	6.2595 mL
	20 mM	0.1878 mL	0.9389 mL	1.8779 mL	4.6947 mL
	25 mM	0.1502 mL	0.7511 mL	1.5023 mL	3.7557 mL
	30 mM	0.1252 mL	0.6260 mL	1.2519 mL	3.1298 mL
	40 mM	0.0939 mL	0.4695 mL	0.9389 mL	2.3473 mL
	50 mM	0.0751 mL	0.3756 mL	0.7511 mL	1.8779 mL
	60 mM	0.0626 mL	0.3130 mL	0.6260 mL	1.5649 mL
	80 mM	0.0469 mL	0.2347 mL	0.4695 mL	1.1737 mL
	100 mM	0.0376 mL	0.1878 mL	0.3756 mL	0.9389 mL

Keywords

Tubercidin

8 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Tubercidin

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Natural Product Library

Antiviral Compound Library

Anti-Aging Compound Library

Nucleotide Compound Library

Antibacterial Compound Library

Antibiotics Library

Microbial Metabolite Library

Targeted Diversity Library

Human Metabolite Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

MCE Kinase Hinge Binder Fragment Library

Publications Citing Use of MedChemExpress (MCE) Tubercidin

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (8)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Tubercidin

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Natural Product Library

Antiviral Compound Library

Anti-Aging Compound Library

Nucleotide Compound Library

Antibacterial Compound Library

Antibiotics Library

Microbial Metabolite Library

Targeted Diversity Library

Human Metabolite Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

MCE Kinase Hinge Binder Fragment Library

Publications Citing Use of MedChemExpress (MCE) Tubercidin

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (8)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Tubercidin Related Classifications

HY-100126 Related Classifications